Literature DB >> 24145838

Melatonin receptors mediate improvements of survival in a model of polymicrobial sepsis.

Tobias Fink1, Michael Glas, Alexander Wolf, Astrid Kleber, Erik Reus, Martin Wolff, Daniel Kiefer, Beate Wolf, Hauke Rensing, Thomas Volk, Alexander M Mathes.   

Abstract

OBJECTIVES: Melatonin has been demonstrated to improve survival after experimental sepsis via antioxidant effects. Yet, recent evidence suggests that this protective capacity may also rely on melatonin receptor activation. Therefore, the present study was designed to investigate whether selective melatonin receptor-agonist ramelteon may influence survival and immune response in a model of polymicrobial sepsis in rats, wild-type and melatonin receptor MT1/MT2 double knockout mice.
DESIGN: Prospective, randomized, controlled study.
SETTING: University research laboratory.
SUBJECTS: Male Sprague-Dawley rats (200-250 g) and male C3H/HeN wild-type and MT1/MT2 receptor knockout mice (20-22 g).
INTERVENTIONS: Animals underwent cecal ligation and incision and remained anesthetized for evaluation of survival for 12 hours (rats: n = 15 per group) or 15 hours (mice: n = 10 per group). Analysis of immune response by means of enzyme-linked immunosorbent assay was performed before and 5 hours after cecal ligation and incision (rats only; n = 5 per group). After induction of sepsis, animals were treated IV with vehicle, different doses of melatonin (rats: 0.01/0.1/1.0/10 mg/kg; mice: 1.0 mg/kg), ramelteon, melatonin receptor-antagonist luzindole, ramelteon + luzindole, or melatonin + luzindole (each 1.0 mg/kg). Sham controls underwent laparotomy but not cecal ligation and incision.
MEASUREMENTS AND MAIN RESULTS: Compared with vehicle, administration of ramelteon or melatonin significantly improved median survival time in rats (sepsis/melatonin [0.1 mg/kg], 554 min, [1.0 mg/kg] 570 min, [10 mg/kg] 579 min; sepsis/ramelteon, 468 min; each p < 0.001 vs sepsis/vehicle, 303 min) and wild-type mice (sepsis/melatonin, 781 min; sepsis/ramelteon, 701 min; both p < 0.001 vs sepsis/vehicle, 435 min). This effect was completely antagonized by coadministration of luzindole in all groups. Melatonin, ramelteon, or luzindole had no significant effect on survival time in knockout mice. Significantly elevated concentrations of tumor necrosis factor-α, interleukin-6, and interleukin-10 were observed 5 hours after cecal ligation and incision in rats (p < 0.05 vs baseline and corresponding sham); neither ramelteon nor melatonin treatment significantly affected immune response.
CONCLUSIONS: Melatonin receptors mediate improvements of survival after polymicrobial sepsis in rats and mice; this effect appears to be independent from major alterations of cytokine release.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24145838     DOI: 10.1097/CCM.0b013e3182a63e2b

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  17 in total

Review 1.  Utilizing melatonin to combat bacterial infections and septic injury.

Authors:  Wei Hu; Chao Deng; Zhiqiang Ma; Dongjin Wang; Chongxi Fan; Tian Li; Shouyin Di; Bing Gong; Russel J Reiter; Yang Yang
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

Review 2.  Timing Matters: Circadian Rhythm in Sepsis, Obstructive Lung Disease, Obstructive Sleep Apnea, and Cancer.

Authors:  Kimberly K Truong; Michael T Lam; Michael A Grandner; Catherine S Sassoon; Atul Malhotra
Journal:  Ann Am Thorac Soc       Date:  2016-07

3.  Administration of Exogenous Melatonin After the Onset of Systemic Inflammation Is Hardly Beneficial.

Authors:  Lisa Brencher; Maren Oude Lansink; Katharina Effenberger-Neidnicht
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

4.  Impact of melatonin receptor deletion on intracellular signaling in spleen cells of mice after polymicrobial sepsis.

Authors:  Astrid Kleber; Sarah Altmeyer; Beate Wolf; Alexander Wolf; Thomas Volk; Tobias Fink; Darius Kubulus
Journal:  Inflamm Res       Date:  2014-10-29       Impact factor: 4.575

5.  Medical hypothesis: Light at night is a factor worth considering in critical care units.

Authors:  Randy J Nelson; A Courtney DeVries
Journal:  Adv Integr Med       Date:  2017-12-21

Review 6.  Management of severe sepsis: advances, challenges, and current status.

Authors:  Ignacio Martin-Loeches; Mitchell M Levy; Antonio Artigas
Journal:  Drug Des Devel Ther       Date:  2015-04-09       Impact factor: 4.162

7.  Melatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential.

Authors:  Eun-Joo Shin; Yoon Hee Chung; Hoang-Lan Thi Le; Ji Hoon Jeong; Duy-Khanh Dang; Yunsung Nam; Myung Bok Wie; Seung-Yeol Nah; Yo-Ichi Nabeshima; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-30       Impact factor: 5.176

8.  Melatonin Pharmacological Blood Levels Increase Total Antioxidant Capacity in Critically Ill Patients.

Authors:  Giovanni Mistraletti; Rita Paroni; Michele Umbrello; Lara D'Amato; Giovanni Sabbatini; Martina Taverna; Paolo Formenti; Elena Finati; Gaia Favero; Francesca Bonomini; Rita Rezzani; Russel J Reiter; Gaetano Iapichino
Journal:  Int J Mol Sci       Date:  2017-04-03       Impact factor: 5.923

9.  Luzindole attenuates LPS/d-galactosamine-induced acute hepatitis in mice.

Authors:  Yisheng Luo; Yongqiang Yang; Yi Shen; Longjiang Li; Jiayi Huang; Li Tang; Li Zhang
Journal:  Innate Immun       Date:  2019-11-28       Impact factor: 2.680

10.  Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis.

Authors:  Luciana Pinato; Sanseray da Silveira Cruz-Machado; Daiane G Franco; Leila M G Campos; Erika Cecon; Pedro A C M Fernandes; Jackson C Bittencourt; Regina P Markus
Journal:  Brain Struct Funct       Date:  2013-12-22       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.